Compare · ARGX vs RXRX
ARGX vs RXRX
Side-by-side comparison of argenx SE (ARGX) and Recursion Pharmaceuticals Inc. (RXRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and RXRX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $53.41B, about 34.2x RXRX ($1.56B).
- Over the past year, ARGX is up 52.5% and RXRX is down 49.7% - ARGX leads by 102.2 points.
- RXRX has been more active in the news (11 items in the past 4 weeks vs 3 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 10 for RXRX).
- Company
- argenx SE
- Recursion Pharmaceuticals Inc.
- Price
- $861.30+0.30%
- $2.94-2.65%
- Market cap
- $53.41B
- $1.56B
- 1M return
- -1.91%
- -7.84%
- 1Y return
- +52.49%
- -49.74%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2021
- News (4w)
- 3
- 11
- Recent ratings
- 25
- 10
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.
Latest ARGX
- argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Latest RXRX
- Director Borgeson Blake sold $158,500 worth of shares (40,000 units at $3.96) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 6,218,287 units (SEC Form 4)
- Director Dar Zavain was granted 5,109 shares, increasing direct ownership by 2% to 240,764 units (SEC Form 4)
- Director Li Dean Y was granted 3,747 shares, increasing direct ownership by 0.25% to 1,473,329 units (SEC Form 4)
- A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
- Director Borgeson Blake was granted 88,424 shares, increasing direct ownership by 1% to 6,258,287 units (SEC Form 4)
- Director Hershberg Robert was granted 88,424 shares, increasing direct ownership by 120% to 162,156 units (SEC Form 4)
- Director Michor Franziska was granted 88,424 shares, increasing direct ownership by 70% to 215,477 units (SEC Form 4)
- Director Sun Elaine D was granted 88,424 shares, increasing direct ownership by 186% to 135,981 units (SEC Form 4)
- Director Dar Zavain was granted 88,424 shares, increasing direct ownership by 60% to 235,655 units (SEC Form 4)
- Director Bumpus Namandje was granted 88,424 shares and sold $12,602 worth of shares (3,963 units at $3.18) as part of a pre-agreed trading plan, increasing direct ownership by 196% to 127,632 units (SEC Form 4)